FDA to ban pharma employees from serving on adcomms
The FDA is looking to further limit pharma companies' involvement in advisory committees that typically review new drugs or safety issues. But the shift away from pharma influence is likely to have...
View ArticleAstraZeneca, Daiichi eye first-line breast cancer market after Enhertu's...
AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of progression or death compared with the standard of care for first-line HER2-positive metastatic breast cancer, the companies said Monday. The...
View ArticleRoche promises $50B investment in the US as pharma tariffs inch closer
Roche is the latest pharma giant with new plans to boost its R&D and manufacturing presence in the US, announcing on Tuesday it has budgeted $50 billion to do so over the next five years ...
View ArticleAs the XBI suffers, Q1 shows a few comforting signs of underlying stability
The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry yearning for better times. Talk to CEOs these days and the mood for ...
View ArticlePreventive health startup Superpower raises $30M
Superpower, a startup that aims to help consumers have more information about their health, raised $30 million. The San Francisco-based company joins a growing group of longevity-focused startups like...
View ArticleDrugmakers stockpile inventory in the US, seeking to get ahead of Trump tariffs
Large pharmaceutical companies that make drugs around the world have begun to ship and stockpile products inside US borders, in an effort to blunt the impact of the Trump administration’s expected...
View ArticleGeorge Church startup Matter Bio will study long-lived animals, humans
The animal kingdom is full of creatures that live longer than expected. Naked mole rats survive three or four decades. Some parrots survive upwards of 60 years, outliving their owners when kept as...
View ArticleDanaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms
Plus, news about Invivyd: Danaher’s tariffs hit: The life sciences company currently expects the costs of tariffs to be “something like $350 million” in 2025, according to CEO Rainer Blair on Tuesday’s...
View ArticleInsurers have a Medicare Advantage problem
How much longer will Medicare Advantage continue to beat up health insurance earnings? For two years now, we’ve been chronicling how higher costs among seniors enrolled in Medicare Advantage (the...
View ArticleGalapagos CEO Paul Stoffels to step down, former Neumora chief to lead spinout
Paul Stoffels joined Galapagos to turn it around three years ago. But after a series of unsuccessful studies, pipeline changes and a bumpy quest into cell therapy, the Belgian biotech's turnaround...
View ArticleRegeneron to boost its US manufacturing through a $3B Fujifilm deal
Fujifilm Diosynth Biotechnologies' bet on its North Carolina biologics facility is paying off, as Regeneron plans to shell out several billion dollars to move manufacturing to the site. Over the next...
View ArticleRecent FDA staff cuts to delay drug hearing decision by months, agency tells...
For the first time since the Trump administration's major staff cuts at the FDA this month, the agency publicly announced that the firings will lead to a long delay for what would otherwise be a ...
View ArticleAstraZeneca rejoins PhRMA, two years after leaving lobby group
British drugmaker AstraZeneca is rejoining the drug industry's major US lobbying group, PhRMA, roughly two years after quitting the organization. As part of its membership, AstraZeneca CEO Pascal...
View ArticleVaccine biotechs get stop-work orders for their next-gen Covid work
At least three biotech companies say they’ve received orders to stop their work related to a Biden administration initiative to advance new Covid-19 vaccines. GeoVax, CastleVax and Vaxart told...
View ArticleBristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment
Bristol Myers Squibb’s attempt to turn Cobenfy into a megablockbuster neuroscience drug ran into a stumbling block Tuesday afternoon. The company said Cobenfy, approved last year for schizophrenia, did...
View ArticleBoehringer taps Tessellate Bio for ALT positive cancer pact exceeding $573M...
Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that maintain telomere length to survive and grow. The Amsterdam-based biotech...
View ArticleEli Lilly sues four telehealth companies selling compounded tirzepatide
Just a few weeks after Eli Lilly sued two large compounding pharmacies, the pharma giant on Thursday filed lawsuits against four telehealth companies over their sale of compounded versions of the GLP ...
View ArticleExclusive: Chicago startup Grove Biopharma nabs $30M Series A
A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A. The startup, named Grove Biopharma, weathered the pandemic and, after more...
View ArticleRepertoire inks autoimmune deal with Genentech as it eyes a return to the clinic
Every few years, Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship Pioneering-incubated startup on Wednesday unveiled a tie-up with Roche's...
View ArticleAkeso reports another Phase 3 win for PD-1xVEGF approach in lung cancer
Akeso said its PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a Phase 3 study in lung cancer patients in China. The readout marks the third late-stage win for...
View Article